Deep Dive Ticker Tape
Article published Mar 11, 2026. Prices below use latest available snapshots.
MDT Price Structure
Loading chart…
Loading timeframes…
Conviction: Medium Status: FRESH DATA — RSI 26.7, approaching entry zone — price $89.89, oversold
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟢 RSI 26.7 (computed, FRESH) — oversold. Price $89.89, -1.6% today, -6.6% 7D, -11.1% 30D. SMA20 ~$96.72 — price -7.1% below SMA. Now IN entry zone. |
| Moat | Moderate-Wide — scale and switching costs |
| Key insight | MDT data is now FRESH after 15+ days stale. The picture is worse than expected: price dropped from $98.61 (stale) to $89.89 (-8.8%). RSI declined from 36.3 to 26.7 — now oversold. Price is now IN the $88-94 entry zone flagged earlier. The PFA franchise (+80% cardiac ablation growth) and MiniMed spinoff catalysts are intact. At RSI 27 in the entry zone, MDT is actionable. |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | 📈 Accumulate | RSI 26.7 oversold, IN entry zone, wide moat. |
| Entry Zone | $88 - $94 | Current $89.89 — IN ZONE |
| Stop-Loss | $79 (-12%) | Below 52-week low ($79.55) |
| Target 1 | $108 (+20%) | Analyst consensus zone |
| Target 2 | $117 (+30%) | All-time high recovery |
Extended analysis
Price Data
| Stock | Price | 1D | 7D | 30D | 3M | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|
| MDT | $89.89 | -1.6% | -6.6% | -11.1% | -9.2% | 27↓ | 🟢 Oversold | 📈 Accumulate |
Price vs Last Deep Dive (03/10 stale)
| Metric | 03/10 (stale) | 03/11 (fresh) | Change |
|---|---|---|---|
| Price | $98.61 (stale) | $89.89 | -$8.72 (-8.8%) |
| RSI | 36.3 (stale) | 26.7 | -9.6 (worsened significantly) |
| SMA20 | $100.61 | ~$96.72 | -$3.89 |
| vs SMA | -2.0% | -7.1% | Much further below SMA |
Update from 03/10: CRITICAL — MDT data is FRESH and shows significant deterioration. Price dropped from $98.61 to $89.89 (-8.8%). RSI fell from 36.3 to 26.7 — now oversold. Price is IN the $88-94 entry zone. The $92 alert has been breached. PFA franchise and MiniMed spinoff catalysts intact. At RSI 27 in entry zone with a dividend aristocrat yield, this is actionable.
Company Overview
One-Liner
Medtronic is the world's largest standalone medical device company — $34B/year spanning cardiovascular, neuroscience, surgical, and diabetes.
Key Segments (Q3 FY2026)
| Segment | Q3 Revenue | Q3 Organic Growth | Key Products |
|---|---|---|---|
| Cardiovascular | $3.457B | +10.6% | PFA/Affera system, TAVR |
| Neuroscience | $2.558B | +2.5% | Spinal fusion, neuro-stim |
| Medical Surgical | $2.173B | +2.7% | Hugo surgical robot |
| Diabetes | $796M | +8.3% | MiniMed (spinning off mid-2026) |
Bull Case
- PFA is a multi-year growth driver — Cardiac Ablation +80% global, +137% US.
- MiniMed spinoff unlocks value — Removes GLP-1 narrative, 100+ bps margin uplift.
- IN entry zone — $89.89 is within the $88-94 target range.
- Dividend aristocrat — 48 years of increases, ~3.0%+ yield.
- Cheapest large-cap medtech — P/E ~26x forward vs BSX 57x, SYK 35x.
Bear Case
- 10-year underperformance — Still below Sept 2021 ATH.
- Hugo is years from revenue — ISRG has 10,763+ systems.
- -6.6% 7D — Active selling pressure.
- Spine is structural drag — Mature, price-deflationary market.
Research Log
| Date | Update |
|---|---|
| 2026-02-22 | Created. Price ~$97.58. RSI ~58. Q3 strongest growth in 10 quarters. |
| 2026-02-26 | $98.61. RSI 36.3. Getting closer to entry zone. |
| 2026-03-03 | OHLC stale. Watch. |
| 2026-03-10 | OHLC still stale (15+ days). |
| 2026-03-11 | FRESH DATA. $89.89 (-8.8% from stale). RSI 26.7 (computed). NOW IN entry zone ($88-94). Accumulate. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| Stale data masked -8.8% deterioration | Price moved into entry zone while data was stale |
| RSI 36 → 27 (oversold) | Selling pressure intensified during data gap |
| $92 alert breached | Entry zone confirmed — actionable |
| Dividend yield now ~3%+ | Income support during recovery |
Open Questions
- What drove the -6.6% 7D decline? (Q4 guidance? Sector rotation?)
- Is PFA growth accelerating in Q4?
- What multiple will MiniMed trade at post-spinoff?
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.